Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

NCT ID: NCT06280040 Phase: N/A Sponsor: Medical University of Vienna Status: Unknown

SUMMARY

The purpose of this study is to evaluate the incidence and severity of retinopathy and opticopathy one year after treatment with hypofractionated stereotactic photon radiotherapy due to uveal melanoma. Patients will be imaged before radiation, as well as 3, 6, 9 and 12 months after radiation using sonography funds photography, optical coherence tomography angiography, oximeter and microperimetry.

KEY ELIGIBILITY CRITERIA

- * Patients with newly diagnosed uveal melanoma, who will be treated with hypofractionated stereotactic photon radiotherapy as part of clinical routine.
- * unwillingness to participate in the study
- * severe media opacity

ENROLLMENT CONTACT

Judith Kreminger, MD

Department of Ophthalmology and Optometry, Medical University Vienna

Vienna, Austria

Phone: 0043 1 40400 48470

Email: judith.kreminger@meduniwien.ac.at

Total sites: 1 | 1 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT06280040) and public sources. Generated by FindMyCure.ai.